Cresco Labs To Report First Quarter 2019 Financial Results On May 29, 2019

ILLINOIS: Cresco Labs Inc., one of the largest vertically integrated multi-state cannabis operators in the United States, will report its financial results for the first quarter ended March 31, 2019 on Wednesday, May 29, 2019 after the market closes.

Cresco-Logo_BlueThe Company will hold a conference call and webcast to discuss its business and financial results on Wednesday, May 29, 2019 at 6 p.m. Eastern Time (5 p.m. Central Time). The conference call may be accessed via Cresco Labs’ investor relations website at investors.crescolabs.com or by dialing 866-688-4235 (409-216-0711 for international callers) and providing conference ID 5478615.

Archived access to the webcast will be available for one year on the Cresco investor relations website.

 

Ohio Board Of Pharmacy Awards Dispensary Certificate Of Operation In Painesville Township

State_of_Ohio_Board_of_pharmacy_logo2C

OHIO: The State of Ohio Board of Pharmacy today awarded a Dispensary Certificate of Operation to Bloom Medicinals, LLC, located at 382 Blackbrook Rd., Painesville Township.

For a list of all Dispensary Certificates of Operation, please click here.

Ohio Board Of Pharmacy Publishes Updated Patient & Caregiver Numbers For April 2019

State_of_Ohio_Board_of_pharmacy_logo2COHIO: The State of Ohio Board of Pharmacy today published updated patient & caregiver numbers for April 2019. These numbers include:

  • 34,225 Recommendations
  • 31,075 Registered patients with recommendations
    • 2,386 Patients with Veteran Status
    • 1,216 Patients with Indigent Status
    • 171 Patients with a Terminal Diagnosis
  • 15,339 Unique patients who purchased medical marijuana (as reported to OARRS by licensed dispensaries)
  • 2,109 Registered Caregiverss

For the full list of program numbers, please visit the Program Update page.

The Benefits Of CBD Oil For Sleep Disorders And Insomnia

One of the most important components of life is sleep. The way we sleep at night largely influences the behavior and performance we provide the next day. More and more people are suffering from a form of chronic sleep disorder. Specialists believe that certain medication can  contribute to insomnia, especially as this disorder is a frequent side effect of antidepressants.

On the other hand, people who are taking sleeping pills, to get rid of insomnia, can become addicted to these drugs. This state of dependence appears when the treatment is stopped. Symptoms like tremors, nausea, anxiety, changes in blood pressure, muscle cramps may then occur.

Since drugs generate addiction and can lead to abuse, people are looking for natural options to minimize the negative effects. In this sense, cannabidiol has become a viable medical alternative. Here is how CBD is not only a healthy alternative to sleeping pills but it can counteract many factors that cause sleep disturbances.

What is Insomnia?

Insomnia is the sensation of inadequate or poor repose due to problematic sleep, frequent night awakening with difficulty in falling asleep again.

Insomnia is classified as:

  • Transient (short-term) – lasting from one night to a few weeks;
  • Intermittent (appears and disappears) – where the episodes appear from time to time;
  • Chronic (constant) – insomnia occurs in most nights, at least three times a week for more than a month.

Insomnia may occur due to emotional, neurological or medical disorders as well as a result of stimulant medications or alcohol/drug addiction.

What Illnesses Can Insomnia Hide?

In most cases, insomnia is based on psychiatric pathology, ie neurosis (depression, anxiety) or psychosis (schizophrenia and related disorders). Insomnia also occurs in thyroid disorders, alongside depression and appetite disorders.

Insomnia may appear in patients with adrenal gland disorders, as well as patients with advanced cirrhosis when hepatic encephalopathy occurs. Last but not least, this disease occurs in patients with cardiac pathology, especially due to decompensation in the evening or at night. 

How Does CBD Work?

CBD works through the endocannabinoid system (ECS). In our body, this system produces its own cannabinoids. ECS regulates processes such as our mood and appetite, as well as our perception of pain.

CBD interacts with the endocannabinoid system and its receptors having numerous beneficial effects as research results suggest.

CBD OilImage source: Pexels.com

The Effects of CBD on Sleep

CBD is a constituent of the plant called cannabis. Another constituent of this plant is THC. Both substances are known for their beneficial effects. However, THC also has a psychoactive effect, unlike CBD. Hemp plants contain a high CBD concentration.

Several studies have shown that CBD can have a medicinal effect on a wide range of health problems. One of these problems is insomnia. CBD not only makes sleeping easier but also influences the sleep cycle.

Sleep divides into several cycles with different phases. Insomnia occurs during the rapid eye movement (REM) stage, called REM parasomnia. In this phase, active behavior and nightmares will take place during dreams. This is a category of sleep disorders that involves behaviors, emotions and abnormal movements. It is also characterized by loss of muscles’ capacity to relax during REM sleep.

Cannabidiols have strong anxiolytic, anticonvulsant and sedative effects. CBD oil has the ability to control these disturbing symptoms because it directly affects CB1 receptors in the brain, an important receptor that is responsible for multiple actions of the central nervous system.

In addition, CBD decreases the duration of REM sleep. By reducing this phase, people dream less, memory improves and symptoms of depression are lowered. Blood tests have shown that CBD oil influences dopamine levels in the blood during sleep. This leads to a better, relaxed sleep alongside lower destructive behavior.

In sleep disturbance, the same component called CBD, by its anxiolytic effect, blocks anxiety states induced in REM sleep state, which makes a person suffering from this disorder have a longer sleeping time; therefore, recover fast from damages provoked by previous insomnia episodes.

Recommended CBD Oil Dosage in Sleeping Disorders?

The first thing to look for, when decided to consume CBD oil, is its purity. This applies in any case, regardless of the medical disorder encountered. If it is not in its pure state, containing 100% CBD oil, this treatment may have weaker results. Moreover, when it is not in a pure state, this oil may comprise other chemicals which promote allergies.

Hellomello.life offers lab-tested, 100% natural CBD oil which may come in handy in treating sleep disorders and insomnia. Unlike other medical treatments, this CBD oil does not give addiction and does not have other side effects on brain chemistry, in neither short or long-term.

For sleep disorders, the recommended CBD oil dosage shall fall between 40 mg-160 mg of CBD taken orally. The exact amount taken depends on the user’s body weight and tolerance, as well as the concentration of CBD per ml of oil. The higher the body weight, the greater is the dosage of CBD oil.

In some cases, users develop a tolerance to the consumption of CBD oil, meaning that once ingested effects take longer to appear. In this case, it is advisable to increase the usual dosage.

Final Thoughts

Cannabidiol (CBD) is a component of Cannabis sativa plant that has an extensive range of potential beneficial effects in neuropsychiatric and other disorders. Insomnia is among disorders that finds its cure in CBD oil.

Sleep is very important for the body’s recovery and if this becomes insufficient it can affect your health. The main cause of insomnia today stays the stress, which in the long run remains harmful to the body.

Among the most common reasons for using CBD oil is the effect of relieving stress and anxiety. Cannabidiol has great efficacy in relaxing the mind, reducing stress and inducing calmness, being a good solution to combat insomnia and sleep disorders.

Tilray Hosts Official Ribbon-Cutting Ceremony At European Union Campus For Medical Cannabis Production and Distribution

The 250,000 square-foot facility located in Cantanhede, Portugal serves as the hub for Tilray’s cultivation, processing, distribution and research of medical cannabis products in Europe

CANADA: Tilray, a global pioneer in the research, cultivation, production and distribution of cannabis today celebrated the official opening of its European Union (EU) Campus located in Cantanhede, Portugal. Tilray CEO Brendan Kennedy, global senior leaders and the EU Campus Team welcomed guests from all over the world including international healthcare professionals, government officials and local dignitaries to celebrate the inauguration of the company’s European production and distribution centre.   
 
For the event, which followed Tilray’s successful outdoor harvest last year and greenhouse harvest earlier this year, guests were invited to attend a ribbon-cutting ceremony and tour Tilray’s state-of-the-art facility. 

Tilray’s EU Campus in Portugal is a multi-faceted production facility that includes indoor, outdoor and greenhouse cultivation sites, as well as research labs, processing, packaging and distribution sites for medical cannabis and cannabinoid-derived medical products. To date, Tilray has invested approximately €20 million in the facility, which totals approximately 250,000 square-feet with additional room to expand. Tilray’s EU Campus also serves as a hub supporting Tilray’s clinical research and product development efforts across Europe. Tilray’s EU Campus currently employs more than 100 professionals, and that number is expected to double by the end of 2019, with production ramping up and multiple harvests anticipated in the coming months. 
 
“We’re thrilled to celebrate another milestone as we continue to expand our global presence and pioneer the future of the cannabis industry. We are grateful for the warm welcome we’ve received from Portugal and the city of Cantanhede,” says Brendan Kennedy, Tilray CEO. “We’re looking forward to utilizing Tilray’s EU Campus to serve the European Union medical cannabis markets with high-quality, pharmaceutical-grade medical cannabis products.”
 
Tilray announced a successful harvest from its EU Campus in February 2019 with multiple harvests expected in the coming months. Tilray looks forward to supplying patients in Europe from its EU Campus when it receives GMP certification.
 

 

 

Cannabis Industry Needs More Budtenders

The Cannabis industry is thriving right now, as more and more states legalize the natural drug for medical consumption and recreational use. The industry is worth an astonishing $50 billion dollars and one of the most in demand positions is what’s known as the budtender.

Budtender’s are the front of house staff, the first people you will see when you visit a Cannabis dispensary when you obtain your Medical Cannabis Prescription. These positions are in huge demand, generally, they have a huge wealth of knowledge and must know about a variety of strains, what they are used for and what they do. Not only this, they are also offer up advice, recommendations and product safety.

This means, anywhere that Cannabis is legal, there are firms headhunting super-savvy sales people with the ability to sell the heck out of as much Cannabis as humanly possible. The salesforce is not for the faint hearted, let’s face it, the Cannabis industry did not grow to be 50 Billion dollars by being passive when it comes to sales.

Dispensaries need very knowledgeable people to push as many grams, oils and edibles into the bags of hundreds of consumers that pass through their doors each day. Those who can do this and focus in on the customer care at the same time are the most successful in the business.

Dispensaries look for people who are very enthusiastic about Cannabis. The best Budtender’s can make in excess of $35-40K in their first year. Most dispensaries start their staff out at $12-14 dollars an hour. It’s a very good sustainable income if you can get it! Let’s face it, Medical Cannabis is a green niche, no pun intended.

So how do you get the job?

To become a budtender, there are some requirements. You can forget thinking that it involves growing dreadlocks, having blazed red stoner eyes and tie-dye clothing. The industry is trying to project an image that goes against the grain of the stereotype. Adding “I have watched get high 50 times” to your CV will not work, so forget that.

Budtender Requirements

  1. Gift of the gab – Budtenders are not just enthusiastic about the products, they also possess a certain finesse when it comes to selling. It is a fine art that is not learnt but something every good salesman possesses. They can answer any question about any product within a split second and turn that answer into a sale.
  2. Knowledge – A good Budtender will always be able to answer any questions on any product immediately. They have extensive knowledge on a wide variety of product. Though dispensaries supply on-the-job training, having knowledge about the different strains will be a bonus.
  3. Customer Service Skills – Customer service is always a must in Business, especially the retail sector. Successful sales people can talk to a customer in such a way that they feel very comfortable and confident that the product they are selling them is what they need.
  4. Highly Organized – Every second is a hustle in any Business on the sales floor. Showing your employer, a great level of determination early-on is the sure-fire way to success in the Business. The Business of sales is a cut-throat world, nobody will carry you through it, it’s a path you learn on your own and put your unique twist on.

 Photo: Jake Dimmock, the original budtender at Seattle’s Diego Pellicer.

FSD Pharma To Establish Presence In Canada’s Insurance Regimes

Signs agreement focusing on exploring insurance coverage for medical cannabis Canada wide

CANADA: FSD Pharma Inc. announced the signing of a consulting agreement with Joseph L. Romano, a well-respected lawyer with a strong track-record in personal injury law. Mr. Romano has been working with medical cannabis since 2006, assisting people coping with chronic pain to have access to medical cannabis, a viable alternative to opioid based medications.

Pursuant to the terms of the agreement, Mr. Romano will provide consulting on the inner workings of third party actions, WSIB claim handling, first party coverage and no fault benefits across Canada. Mr. Romano will also assist in identifying strategic acquisitions that will enhance shareholder value.

Commenting on the agreement, Dr. Raza Bokhari, Executive Co-Chairman and interim CEO said, “We are very excited to engage Mr. Romano in advance of our anticipated sales license. This is a very timely and important agreement for FSD Pharma to maximize the opportunities in the Canadian market for our products and fits well with our strategy of establishing the company as a leader in medical cannabis.”

In consideration for his services, FSD will pay Mr. Romano consulting fees, warrants and shares in the company, subject to compliance with all applicable securities laws and the policies of the Canadian Securities Exchange.

First US Clinical Study Assessing Hemp-Derived Cannabinoid Supplementation In Recovery From Traumatic Brain Injury Begins In Colorado

COLORADO:  The Flowering HOPE Foundation and Clover Leaf University have just announced sponsorship and collaboration on the first US clinical study to be approved to investigate plant-derived cannabinoid supplements in recovery from brain injury. 

The study will analyze quantitative EEG brain activity and a cannabinoid-sensitive salivary biomarker in 40 subjects with mild traumatic brain injury and controls who currently take hemp-derived botanical supplements on a regular basis (i.e. phytocannabinoids). The study is recruiting adults age 18 to 55 to participate in the year-long trial. 

Jason Cranford, Founder of the Flowering HOPE Foundation, a Colorado registered 501(c)(3) nonprofit organization that supports the medicinal use of plant-derived cannabinoids, called phytocannabinoids, described the motivation for sponsoring the study: “We hope to provide scientific support for the benefits of the natural plant-based compounds contained in hemp and move a step closer towards the unrestricted availability of non synthetic cannabinoid therapeutics.”

Cranford is a pioneer in the emerging cannabis industry with more than 25 years experience in cultivation, extraction and formulations. His know-how allowed him to breed a unique hemp strain selected for a blend of phytoterpenes and phytocannabinoids designed to alleviate treatment-resistant epilepsy in children without psychoactive side effects. The resulting strain, called Haleigh’s Hope, was formulated into a supplement offered by the FHF (2013). 

The FHF has partnered with Clover Leaf University to study brain injury. The President and Founder, Chloe Villano, received accredited approval for CLU in 2013 by the Colorado Department of Higher Education’s Private Occupational School Board. Villano is a pioneer in the cannabis and hemp industry and prioritized brain injury for the study.

“This historic study is the first of its kind and it is a privilege to work with the Flowering HOPE Foundation to address the problem of brain injury and collaborate with a neuroscientist who understands the brain endocannabinoid system, such as Dr. Cooper. There are currently no effective treatments for traumatic brain injury or chronic traumatic encephalopathy, but phytocannabinoids may be a good candidate, based on the established science of anti-inflammatory and neuroprotective mechanisms. Clover Leaf University is excited to take the lead in clinical studies that will improve and save lives,” said Villano.

The lead neuroscientist responsible for the study,  Don Cooper, Ph.D, is President of Real-Time Diagnostics Ventures Inc. He has published 45 peer reviewed papers on neuronal memory formation/plasticity and has studied brain cannabinoids since 2000, when he received his first NIH grant. 

“I never thought it would take almost 20 years from when I started working on the brain cannabinoid system to have the first approved clinical study on phytocannabinoids and brain injury. We have convincing preclinical data showing that phytocannabinoids are neuroprotective and may be critically important for restoring neuronal function after brain injury,” stated Cooper.

For more information contact the study Clinical Coordinator at TBIstudy@protonmail.com.

Tilray Announces Successful Medical Cannabis Harvest In Portugal; Provides Update On European Operations

CANADA: Tilray, a global leader in cannabis research, cultivation, production and distribution, announced that its wholly-owned subsidiary Tilray Portugal Unipessoal Lda. has completed a successful harvest of medical cannabis at the Company’s European Union (EU) Campus in Portugal.

Tilray_LogoTilray’s EU Campus in Portugal is a multi-faceted production facility that includes indoor, outdoor and greenhouse cultivation sites, as well as research labs, processing, packaging and distribution sites for medical cannabis and cannabinoid-derived medical products. To date, Tilray has invested approximately €20 million in the facility, which totals nearly 250,000 square-feet with additional room to expand. Tilray’s EU Campus also serves as a hub supporting Tilray’s clinical research and product development efforts across Europe. Tilray’s EU Campus currently employs 100 people, and that number is expected to double by the end of 2019, with production ramping up and multiple harvests anticipated in the coming months.

“Our harvest in Portugal is an exciting milestone for the company as we continue to build our multinational supply chain of high-quality medical cannabis,” said Sascha Mielcarek, Managing Director, Europe. “We look forward to utilizing the capacity of Tilray Portugal to supply the medical cannabis market in Europe as we expand our operations.”

Tilray was the first licensed medical cannabis producer to successfully import medical cannabis products into the EU and the first licensed medical cannabis producer in North America to obtain Good Manufacturing Practice (GMP) certification in accordance with the European Medicines Agency’s (EMA) standards. Tilray has established sales and distribution arrangements to distribute medical cannabis through major pharmaceutical distribution channels throughout Germany and the European Union. The Company has also formed a global alliance with Sandoz AG, a worldwide leader in generic pharmaceuticals and biosimilars and a part of Novartis group, to increase availability of high quality medical cannabis products around the world in jurisdictions where regulations permit.

In addition to its EU Campus in Portugal, Tilray currently operates multiple state-of-the-art production and processing facilities in Canada. Tilray looks forward to hosting an official ribbon-cutting event at its EU Campus in Portugal later this spring.

Ohio Medical Marijuana Sales Figures — March 3, 2019

Update from the Ohio Medical Marijuana Control Program

Update from the Ohio Medical Marijuana Control Program

OHIO:  The following are program sales totals from 1/16/2019 to 3/3/2019:

Total sales: $1,520,381
Total volume of product sold: 201 pounds

The Ohio Medical Marijuana Control Program will provide weekly sales figures through April 1st after which a monthly report will be made available.

Patient registration information will continue to be reported on a monthly basis.